First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma.

First-in-Human Phase I Study of ABBV-838, an Antibody-Drug Conjugate Targeting SLAMF7/CS1 in Patients with Relapsed and Refractory Multiple Myeloma. Clin Cancer Res. 2020 05 15; 26(10):2308-2317.

View in: PubMed

subject areas

Adult
Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized
Cohort Studies
Drug Resistance, Neoplasm
Female
Follow-Up Studies
Humans
Immunoconjugates
Male
Middle Aged
Multiple Myeloma
Neoplasm Recurrence, Local
Prognosis
Salvage Therapy
Signaling Lymphocytic Activation Molecule Family
Tissue Distribution

authors with profiles

Andrzej Jakubowiak